X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs GLENMARK PHARMA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD GLENMARK PHARMA ALEMBIC LTD/
GLENMARK PHARMA
 
P/E (TTM) x 55.4 20.3 272.9% View Chart
P/BV x 3.1 3.6 86.0% View Chart
Dividend Yield % 0.4 0.3 108.0%  

Financials

 ALEMBIC LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-16
GLENMARK PHARMA
Mar-17
ALEMBIC LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs53993 5.3%   
Low Rs29729 4.0%   
Sales per share (Unadj.) Rs4.7325.5 1.4%  
Earnings per share (Unadj.) Rs8.839.3 22.3%  
Cash flow per share (Unadj.) Rs9.048.7 18.5%  
Dividends per share (Unadj.) Rs0.152.00 7.5%  
Dividend yield (eoy) %0.40.2 157.3%  
Book value per share (Unadj.) Rs27.7159.2 17.4%  
Shares outstanding (eoy) m267.03282.17 94.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x8.72.6 328.8%   
Avg P/E ratio x4.721.9 21.3%  
P/CF ratio (eoy) x4.617.7 25.8%  
Price / Book Value ratio x1.55.4 27.4%  
Dividend payout %1.75.1 33.6%   
Avg Mkt Cap Rs m10,962242,991 4.5%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m23816,408 1.5%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m1,26091,857 1.4%  
Other income Rs m264374 70.6%   
Total revenues Rs m1,52492,230 1.7%   
Gross profit Rs m8320,367 0.4%  
Depreciation Rs m612,644 2.3%   
Interest Rs m02,373 0.0%   
Profit before tax Rs m28515,724 1.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m2,0960-   
Extraordinary Inc (Exp) Rs m-32-810 4.0%   
Tax Rs m63,827 0.2%   
Profit after tax Rs m2,34311,088 21.1%  
Gross profit margin %6.622.2 29.6%  
Effective tax rate %2.124.3 8.8%   
Net profit margin %185.912.1 1,540.1%  
BALANCE SHEET DATA
Current assets Rs m1,68968,746 2.5%   
Current liabilities Rs m48627,027 1.8%   
Net working cap to sales %95.445.4 210.1%  
Current ratio x3.52.5 136.6%  
Inventory Days Days21785 255.2%  
Debtors Days Days8196 84.8%  
Net fixed assets Rs m1,62424,132 6.7%   
Share capital Rs m534282 189.3%   
"Free" reserves Rs m5,96044,643 13.4%   
Net worth Rs m7,40444,925 16.5%   
Long term debt Rs m10445,363 0.2%   
Total assets Rs m8,010117,639 6.8%  
Interest coverage x950.77.6 12,466.8%   
Debt to equity ratio x01.0 1.4%  
Sales to assets ratio x0.20.8 20.1%   
Return on assets %29.311.4 255.6%  
Return on equity %31.624.7 128.2%  
Return on capital %31.319.1 163.4%  
Exports to sales %2.90-   
Imports to sales %28.90-   
Exports (fob) Rs m37NA-   
Imports (cif) Rs m364NA-   
Fx inflow Rs m3756,152 0.1%   
Fx outflow Rs m3658,084 4.5%   
Net fx Rs m-32848,068 -0.7%   
CASH FLOW
From Operations Rs m3466,574 5.3%  
From Investments Rs m-48-7,124 0.7%  
From Financial Activity Rs m-3015,432 -5.5%  
Net Cashflow Rs m-31,992 -0.2%  

Share Holding

Indian Promoters % 64.0 48.3 132.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 6.9 2.9%  
FIIs % 9.7 34.4 28.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.5 248.6%  
Shareholders   54,701 56,727 96.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  MERCK LTD  SANOFI INDIA  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Jun 21, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - DR. REDDYS LAB COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS